Clinical Trials Browser

Recruiting × Urinary Bladder Neoplasms × Gemcitabine × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

160 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06388720 2026-04-13

IMGeS

Phase 2 Recruiting

82 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

630 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

Phase 2 Recruiting

25 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06571708 2025-09-02

NeoSTOP-IT

Phase 2 Recruiting

36 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04574960 2025-07-20

NAUTICAL

Phase 3 Recruiting

14 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05024734 2025-03-11

GAIN INST

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Phase 2 Recruiting

41 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

ADAPT-BLADDER

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

IMGeS

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

GAIN-BCG

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Intravesical Gem/Doce in Patients With NMIBC

NeoSTOP-IT

NAUTICAL

GAIN INST

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer